Background
What it is, how it developed and why it is discussed
This concept has referenced BPC-157/TB-500-style products. Those peptides are specifically named by SAHPRA among illegally marketed peptides.
A peptide-containing IV concept that remains subject to South African regulatory restrictions.
A consultation does not guarantee that a product can be supplied.
This treatment is not enabled for routine online sale. A doctor can discuss the evidence, suitability and lawful alternatives. Where an unregistered medicine is considered clinically necessary, any access must follow the applicable SAHPRA authorisation process before supply.
Clinical assessment Clinician authorisation